There's a new frontier in treating autoimmune diseases. Today's treatments tamp down the friendly fire but don't fix what's ...

New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

Early CAR T cell expansion is associated with both therapeutic activity and inflammatory toxicity, such as cytokine release syndrome and neurotoxicity. Routine flow cytometry can reliably track ...

A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...

In this interview, Dr. Kelemen discusses the advantages of lipid-based delivery systems and their potential to expand the ...

Only a few dozen patients with lupus have been treated with CAR-T-cell therapy — but in a small German study, all five ...

Preexisting autoimmune diseases are tied to shorter hospital stays and less toxicity risk in patients receiving chimeric ...

A new systematic review shows CAR T-cell therapy delivers high remission rates, reduced disease activity, and low toxicity in ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under two years, despite standard care involving surgery, radiation, and ...

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the ...